calpain inhibitor III

potential anticataract drug

Also Known As:

CalI III; Cbz-Val-Phe-H; CbzValPheH; MDL 28170; MDL-28170; MDL28170; N-CBZ-Val-Phe-al; N-benzyloxycarbonylvalylphenylalaninal; N-benzyloxycarbonylvalylphenylalanine aldehyde; cBz-ValPheH; carbobenzoxyvalylphenylalanine aldehyde

Networked: 59 relevant articles (16 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Dipeptides: 945
      - calpain inhibitor III: 59

Experts

1.	Branquinha, Marta H: 3 articles (02/2022 - 07/2010)
2.	Santos, André L S: 3 articles (02/2022 - 07/2010)
3.	Oliveira, Simone S C: 2 articles (02/2022 - 10/2017)
4.	Sangenito, Leandro S: 2 articles (02/2022 - 10/2017)
5.	d'Avila-Levy, Claudia M: 2 articles (02/2022 - 07/2010)
6.	Gu, Xiao-Ming: 2 articles (01/2022 - 01/2018)
7.	Lu, Hong-Ting: 2 articles (01/2022 - 01/2018)
8.	Zhou, Jing-Jun: 2 articles (01/2022 - 01/2018)
9.	Chen, Qun: 2 articles (02/2016 - 12/2011)
10.	Hu, Ying: 2 articles (02/2016 - 12/2011)

Related Diseases

1.	Hypoxia (Hypoxemia) 11/01/1993 - "In contrast, synaptic recovery after a fixed period of hypoxia (15 minutes) was significantly improved in the Cbz-Val-Phe-H-treated slices (P < .01). " 01/01/2022 - "In vitro, mouse hippocampal neuronal cells (HT22) were treated with hypoxia (1% O2) for 24 hours in the presence or absence of AS-IV, MDL-28170 (calpain-1 inhibitor), or YC-1 (HIF-1α inhibitor). " 09/19/1997 - "The calpain inhibitor, MDL28170, significantly improved the recovery of synaptic responses in hippocampal slices following prolonged, moderate hypoxia without hypoxic depolarization. " 09/19/1997 - "Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170." 01/01/2016 - "The CCK-8 assay, LDH leakage assay and flow cytometer assay demonstrated that MDL28170 could enhance BMSCs survival in response to Hypoxia-CM and tunicamycin. "
2.	Ischemia 05/08/1998 - "Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia." 02/01/2016 - "MDL-28170 (MDL) was used to inhibit CPN1 in buffer-perfused hearts following 25-min ischemia and 30-min reperfusion. " 12/02/2011 - "Inhibition of calpains using MDL-28170 decreases cardiac injury by inhibiting both cytosolic calpains and mito-μ-calpain during ischemia-reperfusion." 12/02/2011 - "Inhibition of mito-μ-calpain using MDL-28170 decreased cardiac injury by preserving AIF content within mitochondria during ischemia-reperfusion. " 05/08/1998 - "The calpain inhibitor, MDL 28170 (50 mg/kg), was initiated at 0.5 and 3 h of recirculation following 5min of global ischemia. "
3.	Inflammation (Inflammations) 01/01/2019 - "Overall, we found that a single dose of MDL28170 at acute phase of TBI improved the microenvironment by inhibiting the inflammation, facilitated the survival of grafted GFP-BMSCs, and reduced the grafted cell apoptosis, leading to the reduction of lesion cavity. " 05/01/2023 - "MDL28170 inhibited calpain-2 expression, inflammation and autophagy, which suggests its potential efficacy in treating post-CA nerve damage." 01/01/2019 - "The potential mechanisms by which MDL28170 is involved in the regulation of inflammation signaling pathway and cell apoptosis were determined by western blot and immunofluorescence staining. " 05/01/2023 - "However, MDL28170 improved neuronal function and suppressed inflammation and autophagy by inhibiting calpain-2 level, but there were no differences in the calpain-1 and calpastatin levels. " 05/01/2023 - "Calpain inhibitor MDL28170 alleviates cerebral ischemia‑reperfusion injury by suppressing inflammation and autophagy in a rat model of cardiac arrest."
4.	Infarction (Infarctions) 01/01/2014 - "MDL28170, an inhibitor of calpain, prevented ischemia/reperfusion induced increases in LDH and infarct size, improved the LVDP recovery. " 03/01/1994 - "Intravenous injections of cumulative doses of 30 mg/kg or 60 mg/kg of Cbz-Val-Phe-H were effective in reducing infarction, edema, and calcium-activated proteolysis. " 08/01/2010 - "The intravenous infusion of MDL-28170 in an in vivo rat model with transient coronary occlusion during the first minutes of reperfusion resulted in a reduction of infarct size (43.9+/-3.9% vs. 60.2+/-4.7, P=0.046, n=18) and alpha-fodrin degradation. "
5.	Edema (Dropsy) 01/01/2017 - "The MDL28170 treatment significantly reduced the extent of both cerebral contusion (MDL28170 vs. vehicle group, 16.90 ± 1.01 mm΃ and 17.20 ± 1.17 mm΃ vs. 9.30 ± 1.05 mm΃ and 9.90 ± 1.17 mm΃, both P < 0.001) and edema (MDL28170 vs. vehicle group, 80.76 ± 1.25% and 82.00 ± 1.84% vs. 82.55 ± 1.32% and 83.64 ± 1.25%, both P < 0.05), improved neurological scores (MDL28170 vs. vehicle group, 7.50 ± 0.45 and 6.33 ± 0.38 vs. 12.33 ± 0.48 and 11.67 ± 0.48, both P < 0.001), and attenuated NVU damage resulting (including tight junction (TJ), basement membrane, BBB, and neuron) from CCI at 6 h and 24 h. " 03/01/1994 - "Intravenous injections of cumulative doses of 30 mg/kg or 60 mg/kg of Cbz-Val-Phe-H were effective in reducing infarction, edema, and calcium-activated proteolysis. "

Related Drugs and Biologics

1.	calpain inhibitors
2.	Calpain
3.	Calcium
4.	Adenosine Triphosphatases (ATPase)
5.	calpastatin
6.	Matrix Metalloproteinase Inhibitors
7.	Doxycycline (Periostat)
8.	Antioxidants
9.	N- (4- fluorophenylsulfonyl)- L- valyl- L- leucinal
10.	ruboxistaurin

Related Therapies and Procedures

1.	Intravenous Injections
2.	Transplantation
3.	Intraperitoneal Injections
4.	Intravenous Infusions